Teladoc Health (TDOC) shares are seeing a boost in Monday's trading session after a study showed its AI models have contributed to positive growth in diabetes management and engagement with patients.

Yahoo Finance Health Anjalee Khemlani details Teladoc's foray into diabetes treatment through its acquisition of Livongo in 2020.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Luke Carberry Mogan.

Video Transcript

Teladoc High.

What was the news there?

Yeah, that's an interesting one.

So T talk, they had merged with Lavan Go, which is this diabetes management platform.

Back in 2020 they did a huge deal there.

And that is what is coming to for right now because they found through A I and a little bit of research that using that platform and using personalized nudges, for example, leads to greater engagement and reads to lower one C levels.

That's the diabetes uh insulin numbers that the diabetics look at.

So that has been something that um is really contributing to the growth in Teladoc interest as we know, they've suffered through sort of the waning interest in telehealth alone because of post pandemic world.

And so now with this, it really boosts their uh enrollment in chronic care management.

So half of Teladoc enrolled uh enrollment from last year alone was diabetes focused and they said they have more than a million in total on their chronic care platform.

So this is really good news.

Um Just as a reminder, Teladoc will acquire Levon for 18.5 billion in 2020 but then still logged a loss of 13.4 billion in 2022 because of Levon sliding valuation.

So this is looking to still build up on that platform and they're still sort of sticking to it.